These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 21785238)
21. Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Yoshida N; Omoya H; Kato S; Ito T Arzneimittelforschung; 1993 Oct; 43(10):1078-83. PubMed ID: 8267674 [TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological activity of 4-amino-5-chloro-2-ethoxy-3-hydroxybenzamides, metabolites of a new gastroprokinetic agent, mosapride. Kato S; Morie T; Yoshida N Chem Pharm Bull (Tokyo); 1996 Aug; 44(8):1484-92. PubMed ID: 8795267 [TBL] [Abstract][Full Text] [Related]
24. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys. Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675 [TBL] [Abstract][Full Text] [Related]
25. Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulates gastrointestinal motor activity in conscious dogs. Nagahama K; Matsunaga Y; Kawachi M; Ito K; Tanaka T; Hori Y; Oka H; Takei M Neurogastroenterol Motil; 2012 Jun; 24(6):566-74, e256. PubMed ID: 22429221 [TBL] [Abstract][Full Text] [Related]
26. Human prokinetic drugs promote gastrointestinal motility in zebrafish. Zhou J; Guo SY; Zhang Y; Li CQ Neurogastroenterol Motil; 2014 Apr; 26(4):589-95. PubMed ID: 24533865 [TBL] [Abstract][Full Text] [Related]
27. Effects of mosapride on secondary peristalsis in patients with ineffective esophageal motility. Chen CL; Yi CH; Liu TT; Orr WC Scand J Gastroenterol; 2013 Dec; 48(12):1363-70. PubMed ID: 24099237 [TBL] [Abstract][Full Text] [Related]
29. A 5-HT4 agonist, mosapride, enhances intrinsic rectorectal and rectoanal reflexes after removal of extrinsic nerves in guinea pigs. Kojima Y; Nakagawa T; Katsui R; Fujii H; Nakajima Y; Takaki M Am J Physiol Gastrointest Liver Physiol; 2005 Aug; 289(2):G351-60. PubMed ID: 15817810 [TBL] [Abstract][Full Text] [Related]
30. Effects of mosapride on esophageal secondary peristalsis in humans. Chen CL; Liu TT; Yi CH; Orr WC Neurogastroenterol Motil; 2011 Jul; 23(7):606-e249. PubMed ID: 21501334 [TBL] [Abstract][Full Text] [Related]
31. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Asakawa H; Hayashi I; Fukui T; Tokunaga K Diabetes Res Clin Pract; 2003 Sep; 61(3):175-82. PubMed ID: 12965107 [TBL] [Abstract][Full Text] [Related]
32. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Kanaizumi T; Nakano H; Matsui Y; Ishikawa H; Shimizu R; Park S; Kuriya N Eur J Clin Pharmacol; 1991; 41(4):335-7. PubMed ID: 1804650 [TBL] [Abstract][Full Text] [Related]
33. Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study. Keller GA; Czerniuk P; Bertuola R; de Mena F; Simoni MV; Assefi AR; Di Girolamo G Curr Med Res Opin; 2011 Nov; 27(11):2203-11. PubMed ID: 21970660 [TBL] [Abstract][Full Text] [Related]
34. The rodent model of impaired gastric motility induced by allyl isothiocyanate, a pungent ingredient of wasabi, to evaluate therapeutic agents for functional dyspepsia. Hashimoto K; Tashima K; Imai T; Matsumoto K; Horie S J Pharmacol Sci; 2021 Jan; 145(1):122-129. PubMed ID: 33357770 [TBL] [Abstract][Full Text] [Related]
35. Effects of mosapride, a 5-hydroxytryptamine 4 receptor agonist, on electrical activity of the small intestine and cecum in horses. Sasaki N; Okamura K; Yamada H Am J Vet Res; 2005 Aug; 66(8):1321-3. PubMed ID: 16173472 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic analysis of mosapride following intravenous and oral administration in beagle dogs. Kim MS; Baek IH J Vet Pharmacol Ther; 2020 Sep; 43(5):454-460. PubMed ID: 32304239 [TBL] [Abstract][Full Text] [Related]
37. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Ruth M; Hamelin B; Röhss K; Lundell L Aliment Pharmacol Ther; 1998 Jan; 12(1):35-40. PubMed ID: 9692698 [TBL] [Abstract][Full Text] [Related]
38. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Hallerbäck BI; Bommelaer G; Bredberg E; Campbell M; Hellblom M; Lauritsen K; Wienbeck M; Holmgren LL Aliment Pharmacol Ther; 2002 May; 16(5):959-67. PubMed ID: 11966505 [TBL] [Abstract][Full Text] [Related]
39. Effects of food intake on pharmacokinetics of mosapride in beagle dogs. Chae JW; Song BJ; Baek IH; Yun HY; Ma JY; Kwon KI J Vet Pharmacol Ther; 2015 Oct; 38(5):497-9. PubMed ID: 25622855 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of the gastrokinetic agent mosapride citrate after intravenous and oral administrations in dogs and monkeys. Sakashita M; Mizuki Y; Yamaguchi T; Miyazaki H; Sekine Y Arzneimittelforschung; 1993 Aug; 43(8):864-6. PubMed ID: 8216444 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]